Resmed Stock Price, News & Analysis

ResMed's recent study highlights that sleep apnea patients can experience significant health benefits from just 2-3 hours of nightly PAP (positive airway pressure) usage. An analysis of 180,000 users found that each additional hour of PAP use reduces hospitalizations by 5% and emergency room visits by 4.4%. The study suggests that health systems should adapt their guidelines, as benefits extend up to 7 hours of use. Currently, Medicare requires a 4-hour minimum for adherence, which may hinder patient care. The study aims to reshape how healthcare professionals prescribe PAP therapy.

ResMed (NYSE: RMD) has announced the immediate departure of Jim Hollingshead, who served as the President of Sleep and Respiratory Care, after 12 years with the company. Rob Douglas has been appointed as interim President. CEO Mick Farrell acknowledged Hollingshead’s significant contributions to ResMed, particularly in digital health transformation. The transition aims to maintain strong leadership as the company positions itself for continued growth into 2025 and beyond.

ResMed reported a 12% year-over-year revenue increase to $864.5 million in Q3 2022, with a 14% rise on a constant currency basis. Operating profit grew by 5%, and diluted EPS reached $1.22. Despite a contraction in gross margins due to higher costs, strong demand in the sleep and respiratory care sector contributed to sales growth. The company faces supply chain challenges but maintains a positive outlook for its long-term strategy, aiming to impact 250 million lives by 2025.

ResMed (NYSE: RMD) announced that CFO Brett Sandercock will present at the Macquarie Australia Conference on May 3, 2022, starting at 8:45 a.m. Australian Eastern Standard Time. The presentation will be available via video webcast, with a replay accessible 24 hours after the live event until August 1, 2022. ResMed specializes in digital health technologies and cloud-connected medical devices aimed at improving the quality of life for individuals suffering from chronic diseases such as sleep apnea and COPD in over 140 countries.

ResMed (NYSE: RMD) plans to release its financial and operational results for Q3 of fiscal year 2022 on April 28, 2022, post-market close. Following this, management will host a webcast to discuss the results and other relevant information. The webcast will be available internationally, with details for various time zones provided. A replay of the earnings call will be accessible approximately two hours post-webcast. ResMed focuses on innovative solutions for chronic diseases, impacting healthcare quality and costs.

ResMed (NYSE: RMD) announces participation of CEO Mick Farrell in a virtual fireside chat at the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum on March 22, 2022, at 1:30 p.m. EDT. The event will be available via webcast, with a replay accessible within an hour after the live session. ResMed focuses on innovative healthcare solutions for chronic diseases, supporting better patient care through digital health technologies and cloud-connected devices, operating in over 140 countries.

ResMed (NYSE: RMD) announces that Rob Douglas, president and COO, will present at the Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022, at 1:20 p.m. EDT. The presentation will be accessible via a live webcast, with a replay available for viewing through June 13, 2022. ResMed specializes in developing innovative solutions for chronic diseases like sleep apnea and COPD, focusing on digital health technologies and cloud-connected medical devices that enhance patient care and reduce healthcare costs globally.

ResMed (NYSE: RMD) announces that CEO Mick Farrell will participate in a virtual fireside chat at the Citi Healthcare Conference on February 23, 2022, at 12:30 p.m. EST. This event will be accessible via webcast, with a replay available for 24 hours post-event until February 23, 2023. ResMed specializes in innovative solutions for chronic diseases, particularly focusing on digital health technologies and cloud-connected medical devices aimed at enhancing patient care and reducing healthcare costs globally.